SARS-CoV-2 mRNA domain vaccine
MRNA vaccines encoding SARS-CoV-2 spike protein domains in lipid nanoparticles address the lack of COVID-19 treatments by inducing potent neutralizing antibody responses, offering effective protection against the virus.
JP7832243B2Active Publication Date: 2026-03-17MODERNATX INC
View PDF -1 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2024-02-20
- Publication Date
- 2026-03-17
Abstract
To solve the problem in which currently, there is no specific treatment for COVID-19 or vaccine for SARS-CoV-2 infection; the continuing health problems and mortality associated with coronavirus infections, particularly the SARS-CoV-2 pandemic, are of tremendous concern internationally; and the public health crisis caused by SARS-CoV-2 reinforces the importance of rapidly developing effective and safe vaccine candidates against these viruses.SOLUTION: The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines, methods of using the vaccines, and compositions comprising the vaccines. The RNA vaccines encode domains and subunits of the coronavirus.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art